1. Home
  2. AMSC vs TSHA Comparison

AMSC vs TSHA Comparison

Compare AMSC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Superconductor Corporation

AMSC

American Superconductor Corporation

HOLD

Current Price

$32.09

Market Cap

1.7B

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$6.18

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMSC
TSHA
Founded
1987
2019
Country
United States
United States
Employees
400
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
AMSC
TSHA
Price
$32.09
$6.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$52.00
$11.63
AVG Volume (30 Days)
765.5K
2.5M
Earning Date
05-20-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
1806.25
5.56
EPS
0.20
N/A
Revenue
$900,000.00
$9,773,000.00
Revenue This Year
$34.98
N/A
Revenue Next Year
$21.38
$1,152.42
P/E Ratio
$160.65
N/A
Revenue Growth
N/A
17.28
52 Week Low
$24.87
$2.72
52 Week High
$70.49
$7.30

Technical Indicators

Market Signals
Indicator
AMSC
TSHA
Relative Strength Index (RSI) 45.22 50.73
Support Level $29.35 $6.11
Resistance Level $33.70 $7.06
Average True Range (ATR) 1.98 0.35
MACD 0.46 0.01
Stochastic Oscillator 69.94 56.69

Price Performance

Historical Comparison
AMSC
TSHA

About AMSC American Superconductor Corporation

American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: